News | August 24, 2021
Lasa Super Generics open for business
Floods had forced the plans in Mahad to shut down
Floods had forced the plans in Mahad to shut down
This is the first of its kind vaccine for Covid 19 to get the go-ahead
The company is confident of commencing production at both Mahad and Chiplun units soon
Revenues from operations for FY21 stood at Rs. 202.38 crore as compared to 167.27 crore, up by 21%
In some countries such as France, Italy, Spain and the Balkan region, Menarini Group will lead the commercialisation effort, as part of an exclusive licensing agreement signed with Glenmark
Lasa Supergenerics Limited has received WHO GMP Certificate for its manufacturing facility situated at Khed in Ratnagiri.
AI-powered cardiometabolic wellness platform for India’s workforce
The EIR was issued with an inspection classification of Voluntary Action Indicated (VAI) post the inspection conducted in June 2025
Speakers for the Session are: Venkata Prasad K., Unit Head, Deepak Nitrite; Abhilash Pasham, Associate General Manager - Central Engineering & Projects, Dr. Reddy's Laboratories; C. V. Rajulu, Consultant, Industry; and Jyoti Shankar Jha, Senior Lead Scientist, Alleima India. The moderator for the Session is Pravin Prashant, Executive Editor, Indian Pharma Post
Cadila Pharmaceuticals has introduced Dlorfast-M-Tablets as a dual-action therapy that targets two key pathways of allergic response
Subscribe To Our Newsletter & Stay Updated
